Two Decades of Development: The Growth Footprint of Baotai Pharmaceutical


Release time:

2022-07-28

Baotai (Hangzhou) Pharmaceutical has been deeply engaged in global pharmaceutical cross-border trade for nearly twenty years, witnessing and growing alongside the evolution of the international healthcare industry.

Baotai (Hangzhou) Pharmaceutical has been deeply engaged in global pharmaceutical cross-border trade for nearly twenty years, witnessing and growing alongside the evolution of the international healthcare industry. The core founding team stepped into pharmaceutical foreign trade back in the mid-2000s, accumulating profound practical experience in overseas regulatory declaration, product certification and global channel layout through years of market exploration. In 2016, the company completed formal corporate registration, marking a crucial shift toward standardized management, standardized process and large-scale business operation.

Facing changing global market demands, the enterprise launched comprehensive strategic upgrading at the end of 2018, abandoning low-value generic drug trading and marching into high-standard GMP-compliant markets. In 2020, the headquarters officially settled in Hangzhou, taking full advantage of the Yangtze River Delta’s abundant talent reserve, complete industrial supporting and convenient logistics conditions. Successive offices were set up in Linping District of Hangzhou and Chengdu to expand regional service coverage. By 2023, annual business volume successfully exceeded 7.5 million US dollars, demonstrating strong anti-risk capability and sustainable growth momentum. Up to now, we have grown into a pivotal bridge connecting premium Chinese pharmaceutical production capacity with booming emerging markets across the globe.

Get Free Product Quotes

Fill in your email, we will contact you promptly within one business day to resolve the issue you raised as soon as possible.

SUBMIT